1. Home
  2. MBIO vs VRAX Comparison

MBIO vs VRAX Comparison

Compare MBIO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.53

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

VRAX

Virax Biolabs Group Limited

N/A

Current Price

$2.73

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBIO
VRAX
Founded
2015
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
2.1M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MBIO
VRAX
Price
$0.53
$2.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
20.0K
481.1K
Earning Date
05-13-2026
06-12-2026
Dividend Yield
N/A
N/A
EPS Growth
98.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.10
52 Week High
$1.84
$13.19

Technical Indicators

Market Signals
Indicator
MBIO
VRAX
Relative Strength Index (RSI) 37.45 48.44
Support Level $0.53 $2.55
Resistance Level $0.66 $3.10
Average True Range (ATR) 0.02 0.21
MACD 0.00 -0.03
Stochastic Oscillator 0.41 20.27

Price Performance

Historical Comparison
MBIO
VRAX

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: